In a nutshell This study aimed to determine the rate of cancer cases in patients with polyps that were removed surgically. Factors that predict the presence of cancer in these polyps were also investigated. The results confirm the fact that the best therapeutic option for polyps that cannot be removed endoscopically is radical surgery. Some background...
Read MoreType(s) of colorectal cancer (CRC)-Adenocarcinoma of the appendix Posts on Medivizor
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as primary treatment for patients with metastatic colorectal cancer
In a nutshell The present clinical trial compared two chemotherapy regimens as first-line treatment for patients with metastatic colorectal cancer (mCRC): XELIRI-bevacizumav versus FOLFIRI-bevacizumab. Some background Approximately one quarter of patients with colorectal cancer (cancer in the large intestine) have metastases,...
Read MoreTowards guidelines to prevent colorectal cancer recurrence
This article presents results of recent studies concerning the interplay between the body's chemistry and behavioral factors that influence colorectal cancer (CRC) recurrence. Recent advances in CRC treatment have produced new and promising biological treatments. However, tumors sometimes have unique features that render many of these therapies...
Read MoreTreating tumors of the appendix to reduce the risk of spread to the abdominal cavity
In a nutshell The present study classified tumors of the appendix and reviewed treatments that aim to prevent cancer spread to the abdominal cavity. Some background Pseudomyxoma peritonei (PMP) is a rare condition caused by the production of too much mucin (a protein that is secreted in mucus). PMP affects women more than men and symptoms...
Read MoreCombining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation
In a nutshell The present study evaluated whether combining Bevacizumab (Avastin) with chemotherapy for patients with stage IV (metastatic) colorectal cancer (CRC) has any benefits in the terms of survival and quality of life. Main findings: Bevacizumab may be beneficial only as part of certain chemotherapy regimens. Some...
Read MoreEvaluating the benefits of postoperative chemotherapy for patients with stage II colorectal cancer
In a nutshell This study tested whether chemotherapy after surgery (adjuvant chemotherapy) extends survival and reduces the risk of cancer recurrence in patients with stage II colorectal cancer (CRC). Some background Stage II colorectal cancer (cancer in the colon or rectum) is confined to the digestive tract. It is usually treated with surgery...
Read MoreHow soon after surgery for colorectal cancer should chemotherapy be started?
In a nutshell The present study evaluated the association between time until initiation of adjuvant chemotherapy and survival in colorectal cancer patients. The main findings were that a shorter time until adjuvant chemotherapy improves survival rates in patients with resected colorectal cancer. Some background Colorectal cancers that are within...
Read MoreComparing the benefits of two drug combinations as adjuvant chemotherapy for patients with stage III colon cancer
In a nutshell The present study compared the survival benefits of two drug combinations used for adjuvant chemotherapy: Capecitabine/Oxaliplatin (Xelox) versus Fluorouracil/Folinic Acid (FU/FA). The study found Xelox to be a superior therapy for stage III colon cancer. Some background Stage III colon cancer is cancer...
Read MoreWhat is the preferred duration of post-operative chemotherapy for stage II and III colorectal cancer?
Colorectal cancer (CRC) is one of the main causes of cancer related deaths. Patients diagnosed with CRC are treated with surgery to remove the tumor and affected tissue. If the tumor affects the entire thickness of the colon or rectal wall it is referred to as being stage II; if the local lymph nodes are also affected the cancer is referred to as being a...
Read MoreChemotherapy for cancers of the appendix when surgery is not an option
In a nutshell This paper assessed the benefits of giving systemic (whole-body) chemotherapy in cancers of the appendix, when surgery combined with intraperitoneal chemotherapy was not an option. Some background Cancers of the appendix are rare, accounting for about 1% of all colon cancers. However, some of these tumors are aggressive and quickly...
Read More
